GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Placebo ELLIPTA inhaler
Other: Questionnaire

First Posted Date: 2015-10-26

Last Posted Date: 2017-10-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 259

Registration Number: NCT02586506

Locations: 🇺🇸
GSK Investigational Site, Waco, Texas, United States

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

First Posted Date: 2015-10-21

Last Posted Date: 2018-08-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 430

Registration Number: NCT02581410

Locations: 🇺🇸
GSK Investigational Site, Marshfield, Wisconsin, United States

Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Dutasteride-Test product
Drug: Dutasteride-Reference product

First Posted Date: 2015-10-19

Last Posted Date: 2018-06-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02578953

Locations: 🇯🇵
GSK Investigational Site, Fukuoka, Japan

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Batefenterol + Fluticasone Furoate
Drug: Placebo
Drug: Albuterol

First Posted Date: 2015-10-12

Last Posted Date: 2020-07-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 63

Registration Number: NCT02573870

Locations: 🇺🇸
GSK Investigational Site, McKinney, Texas, United States

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Batefenterol
Drug: Umeclidinium/ Vilanterol
Drug: Placebo

First Posted Date: 2015-10-07

Last Posted Date: 2019-07-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 325

Registration Number: NCT02570165

Locations: 🇿🇦
GSK Investigational Site, Thabazimbi, South Africa

A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia

Not Applicable

Completed

Conditions: Dengue

Interventions: Procedure: Blood sample collection

First Posted Date: 2015-10-07

Last Posted Date: 2020-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2004

Registration Number: NCT02570152

Locations: 🇱🇰
GSK Investigational Site, Colombo, Sri Lanka

A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.

Phase 3

Completed

Conditions: Chicken-pox Illness (Varicella Virus Disease)
Chickenpox

Interventions: Biological: Varilrix™
Biological: Varilrix HSA-free

First Posted Date: 2015-10-07

Last Posted Date: 2019-11-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1236

Registration Number: NCT02570126

Locations: 🇬🇧
GSK Investigational Site, Southampton, United Kingdom

Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.

Completed

Conditions: Acellular Pertussis
Tetanus
Aspergillosis, Allergic Bronchopulmonary
Diphtheria
Diphtheria-Tetanus-acellular Pertussis Vaccines

Interventions: Other: Pertussis maternal immunization

First Posted Date: 2015-10-07

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02569879

Locations: 🇨🇴
GSK Investigational Site, Bogota, Colombia

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

Phase 1

Completed

Conditions: Cachexia

Interventions: Drug: GSK2881078
Drug: Placebo
Drug: Itraconazole

First Posted Date: 2015-10-05

Last Posted Date: 2017-03-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 108

Registration Number: NCT02567773

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age

Completed

Conditions: Acute Otitis Media
Pneumonia

Interventions: Other: Data collection

First Posted Date: 2015-10-05

Last Posted Date: 2019-06-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02567747

Locations: 🇨🇴
GSK Investigational Site, Bogota, Colombia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy